Third Line Trials

1. ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01244191

This study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer who have received 1 or 2 prior systemic anti-cancer therapies.
British Columbia
Victoria

Alberta
Edmonton

Manitoba
Winnipeg

Quebec
Montreal
Sainte-Foy

Ontario
Thunder Bay
Princess Margaret Hospital, Toronto
London

2. LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01828112

The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.
Ontario
Toronto

3. A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01712217

This is a 3-part phase 1-2 study in patients with anaplastic lymphoma kinase (ALK) + or other potentially crizotinib-sensitive NSCLC who have been receiving crizotinib. Part A is a single-arm, Phase 1, open-label, dose escalation design in patients with NSCLC who have already been receiving crizotinib for at least 8 weeks and continue to tolerate therapy. Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the maximum tolerated dose established in Part A. Part C is an open-label, randomized, Phase 2, Simon's 2 stage design evaluating single agent AT13387 or combination AT13387 + crizotinib at the MTD established in Part A in patients who progressed on crizotinib at any time.
Nova Scotia
Atlantic Clinical Cancer Research Unit, Halifax

Quebec
McGill University Health Center, Montreal
Institut Universitaire de Cardiologie et de Pneumologie De Quebec, St-Foy

Ontario
Princess Margaret Hospital, Toronto

Manitoba
Cancer Care Manitoba, Winnipeg

4. A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ATLANTIC)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02087423

A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen.
Ontario
Hamilton
London
Ottawa
Toronto

Quebec
Montreal

Saskatchewan
Regina

5. Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.

ClinicalTrials.gov Identifier: NCT02335944

The study determines the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EGF816 in combination with INC280 and to estimate the preliminary anti-tumor activity of EGF816 in combination with INC280 in patients with advanced non-small cell lung cancer (NSCLC) with documented EGFR mutation.
Alberta
Edmonton

6. AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02151981

A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene.
Alberta
Edmonton

British Columbia
Vancouver

Nova Scotia
Halifax

Ontario
Ottawa
Toronto

Quebec
Montreal

7. A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non-Small Cell Lung Cancer With Specific Molecular Alterations

ClinicalTrials.gov Identifier: NCT01970865

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non-small cell lung cancer patients.
Alberta
Cross Cancer Institute, Edmonton

8. Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI (TIGER-2)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02147990

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib, given as oral tablets at a dose of 625mg twice a day, to participants whose tumors did not respond or stopped responding to treatment with their first EGFR TKI medication and who have a T790M positive tumor. The trial is open-ended, which means patients will continue to take rociletinib until the study doctor determines it is no longer beneficial for them.
Ontario
Princess Margaret Hospital, Toronto

9. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02352948

This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).
Alberta
Calgary

New Brunswick
Moncton
Saint John

Ontario
Barrie
London
Newmarket
Thunder Bay
Toronto

10. Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02134015

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy.
Quebec
Levis
Montreal

Ontario
Toronto
Hamilton
Kingston

11. BMS-986012 in Relapsed/Refractory SCLC

ClinicalTrials.gov Identifier: NCT02247349

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 in subjects with relapsed/refractory SCLC.
Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Hospital, Toronto

12. Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02393625

This is an open label multi-center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients.
Ontario
Toronto

13. Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC (ASTRIS)

ClinicalTrials.gov Identifier: NCT02474355

The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
British Columbia
Burnaby
Vancouver

Ontario
Hamilton
North York
Oshawa
Toronto

Saskatchewan
Regina

Quebec
Montreal

14. ELUXA 1: Phase II Trial of HM61713 (BI 1482694) for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02485652

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Ontario
Toronto

Quebec
Montreal

15. TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

ClinicalTrials.gov Identifier: NCT02503722

This phase I trial studies the side effects and best dose of transducer of regulated CREB activity 1/2 (TORC1/2) inhibitor INK128 when given together with epidermal growth factor receptor (EGFR) inhibitor AZD9291in treating patients with advanced EGFR mutation positive non-small cell lung cancer that has spread to other places in the body (advanced) and has progressed after treatment with an EGFR tyrosine kinase inhibitor. TORC1/2 inhibitor INK128 and EGFR inhibitor AZD9291 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Ontario
Princess Margaret Hospital, Toronto

16. A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

ClinicalTrials.gov Identifier: NCT02750514

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab alone in people with advanced Lung cancer.
Alberta
Edmonton

Ontario
Ottawa

17. Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

ClinicalTrials.gov Identifier: NCT02544633

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase number of gene copies]).
Quebec
McGill University Health Centre, Montreal

18. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02414139

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC).
Ontario
Novartis Investigative Site, Ottawa

19. A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

ClinicalTrials.gov Identifier: NCT02387216

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to OS in patients with heregulin-positive NSCLC.
Ontario
Toronto

20. A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

ClinicalTrials.gov Identifier: NCT02108964

A Phase I/II, Multi-center, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies.
Ontario
Toronto